Risk adjusted net present value: What is the current valuation of Rallybio’s RLYB-116?
RLYB-116 is a fusion protein commercialized by Rallybio, with a leading Phase I program in Myasthenia Gravis.
RLYB-116 is a fusion protein commercialized by Rallybio, with a leading Phase I program in Myasthenia Gravis.
What's Your Reaction?
